Dublin, April 24, 2026 (GLOBE NEWSWIRE) — The “Mental Health Clinical Trials Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The mental health clinical trials market has experienced robust growth and is forecasted to continue on this trajectory. Projections estimate an increase from $3.23 billion in 2025 to $3.52 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. This upward trend is driven by a surge in mental health disorder prevalence, expanded pharmaceutical research, heightened awareness, and increased funding for clinical research.
The market is expected to reach $4.89 billion by 2030, growing at a CAGR of 8.6%. This growth will be fueled by the rising adoption of digital mental health interventions, significant investments in personalized psychiatry, expansion of global trial networks, and supportive regulatory frameworks for innovative designs. Key trends shaping the market include the adoption of decentralized trial models, digital therapeutics, AI for patient recruitment, and enhanced remote monitoring.
The increased incidence of mental health disorders is a primary growth driver, with stress factors related to modern lifestyles contributing significantly. As reported by the American Psychiatric Association, anxiety levels among U.S. adults have risen from 32% in 2022 to 43% in 2024. Clinical trials continue to play a pivotal role in advancing treatment by evaluating new drugs, therapies, and interventions for mental health conditions.
Innovative solutions like software-enhanced drug therapies are gaining traction, offering personalized treatment, improved adherence, and real-time support. For instance, in October 2024, Click Therapeutics Inc. launched Click SE, integrating prescription software with pharmacotherapy to offer additional clinical benefits and novel endpoints. This product line supports various mental health conditions through structured programs, real-time tracking, and medication-specific digital support.
In March 2025, Wysa collaborated with April Health Inc. to embed its AI coach into primary care settings, expanding access to mental health services and optimizing care through continuous digital engagement. April Health is known for delivering evidence-based mental health services via primary care platforms.
Leading companies in this market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., and others. North America was the largest market region in 2025, with Asia-Pacific projected to be the fastest-growing region by 2030. The report covers several geographic markets including Australia, China, India, USA, and the UK among others.
Tariffs pose a significant challenge by increasing costs of imported digital devices and platforms essential for trials, leading to increased operational expenses. However, this also prompts local sourcing and regional partnerships, enhancing domestic research capabilities.
The mental health clinical trials market report offers comprehensive insights into global market statistics, regional shares, key competitors, and detailed segment analysis. It provides a holistic view of current and future market scenarios, helping stakeholders navigate the evolving landscape.
The market encompasses revenues from study design, patient recruitment, clinical monitoring, and more. The value includes goods and services traded or sold directly to consumers and is measured in USD. Revenues from resales along the supply chain are excluded.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026 – 2030 |
| Estimated Market Value (USD) in 2026 | $3.52 Billion |
| Forecasted Market Value (USD) by 2030 | $4.89 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Global |
Key Technologies & Future Trends
- Artificial Intelligence & Autonomous Intelligence
- Biotechnology, Genomics & Precision Medicine
- Digitalization, Cloud, Big Data & Cybersecurity
- Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
- Immersive Technologies (AR/VR/XR) & Digital Experiences
- Increasing Adoption of Decentralized Clinical Trial Models
- Rising Use of Digital Therapeutics in Trials
- Growing Integration of AI-Based Patient Recruitment Tools
- Expansion of Remote Patient Monitoring in Studies
- Enhanced Focus on Real-World Evidence Generation
Scope of the Report
- Phase:Phase I through Phase IV
- Study Design:Interventional, Observational, Other Designs
- Disorder:Anxiety, Depression, Bipolar Disorder, Schizophrenia, Others
- Sponsor:Pharmaceutical and Biopharmaceutical Companies, Government Agencies, Others
Companies Featured
- Pfizer Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- AbbVie Inc.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- GSK plc
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- IQVIA Holdings Inc.
- Biogen Inc.
- ICON plc.
- Parexel International Corporation
- CMIC Holdings Co. Ltd.
- Medpace Holdings Inc.
- PSI CRO AG.
- Supernus Pharmaceuticals Inc.
- Worldwide Clinical Trials, Inc.
- Ergomed
- Celerion Inc.
- Biotrial S.A.S.
- Lindus Health Ltd.
- Novotech Health Holdings Pte Ltd.
- Precision for Medicine Inc.
For more information about this report visit https://www.researchandmarkets.com/r/4pq3al
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Mental Health Clinical Trials Market
